Logo

CUPR

Cuprina Holdings (Cayman) Limited Class A Ordinary Shares

CUPR

Cuprina Holdings (Cayman) Limited Class A Ordinary Shares • NASDAQ
$0.68 ▲ 4.26% (+0.03)
Market Cap $13.82 M
52w High $9.50
52w Low $0.61
Dividend Yield 0%
P/E -11.33
Volume 31.42K
Outstanding Shares 20.32M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q4-2024 $116.472K ▲ $1.745M ▲ $6.205M ▲ $-4.46M ▼
Q2-2024 $74.86K ▲ $1.696M ▲ $5.299M ▲ $-3.602M ▼
Q4-2023 $35.263K ▼ $1.586M ▲ $4.483M ▲ $-2.897M ▼
Q2-2023 $176.283K ▼ $1.306M ▼ $3.537M ▲ $-2.231M ▼
Q4-2022 $564.576K $1.436M $3.214M $-1.778M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow

Five-Year Company Overview

Income Statement

Income Statement CUPR looks like a very early-stage, pre-commercial biotech platform. The available history shows essentially no meaningful revenue and small ongoing losses per share, which is typical for a young biotech or a SPAC structure before a full operating business is reflected in the accounts. In practical terms, this means the story today is almost entirely about future potential rather than current profitability or scale. Any path to sustainable earnings will depend on successfully commercializing its wound-care products, medical waste solutions, and related therapies over the coming years.

Balance Sheet

Balance Sheet The balance sheet data provided is effectively blank, which suggests either incomplete reporting in this dataset or that historical figures from the SPAC shell have not been fully integrated. That makes it hard to judge the company’s current financial strength, cash buffer, or leverage from this snapshot alone. For a business with no meaningful revenue yet, future funding needs, access to capital, and the structure of any SPAC trust cash or follow-on financing will be key issues to watch, even though they are not visible here.

Cash Flow

Cash Flow Reported cash flow figures are also effectively zero across the board, which again points more to missing or placeholder data than to economic reality. For a company actively developing multiple products and partnerships, there will almost certainly be cash outflows for research, regulatory work, and business development that are not captured in this summary. Without clear cash flow disclosure, it is difficult to gauge how quickly the company is burning cash, how long existing resources might last, or how dependent it may be on new capital raises.

Competitive Edge

Competitive Edge CUPR is trying to build a niche position in wound care and related medical services by focusing on nature-based, biosurgical solutions that most large device and dressing companies ignore. Its maggot therapy product, leech-based treatments, and licensed waste-recycling technology create a differentiated profile rather than competing head‑on with mainstream wound dressings. The company’s moat rests on specialized know-how, regulatory approvals for unusual biologic therapies, academic partnerships, and exclusive regional licenses. The flip side is that it operates in relatively narrow, sometimes unfamiliar treatment areas where physician adoption, patient acceptance, and reimbursement can be slower and less predictable than for conventional products. Execution in educating clinicians and navigating regulations will be critical to turning this niche positioning into a durable advantage.

Innovation and R&D

Innovation and R&D Innovation is the clear centerpiece of the CUPR story. The company is pushing several nature-inspired platforms at once: sterile maggot dressings for debriding chronic wounds, bullfrog-skin collagen dressings co-developed with a major university, medicinal leech therapies, and an iodine-based antiseptic line. On top of that, it is moving into medical waste recycling using licensed high-temperature steam technology, and exploring cosmeceuticals built on its collagen expertise. This breadth shows strong creativity and a willingness to partner, but it also adds complexity: multiple pipelines, regulatory pathways, and commercialization strategies must be managed in parallel. The value of this R&D will depend on clinical outcomes, regulatory clearances, manufacturing reliability, and whether CUPR can convert promising science into products that hospitals and clinics use at scale.

Summary

CUPR is best understood as an early-stage, innovation-driven healthcare platform emerging from a SPAC background, with financials that currently tell us very little beyond the fact that it is pre-revenue and loss-making. The investment case, risks, and opportunities are dominated by its technology and partnerships rather than by existing earnings or assets. On the opportunity side, it targets underserved corners of wound care and medical waste management with distinctive, nature-based solutions and has assembled a web of collaborations and exclusive licenses that could support future growth. On the risk side, it must prove product effectiveness and safety in broader practice, win over clinicians and regulators to unconventional therapies, build out commercial infrastructure, and secure sufficient funding, all starting from a small base. Until clearer financial statements and commercialization milestones emerge, the company remains a high-uncertainty, pipeline-and-execution story rather than a mature operating business.

NEWS

November 28, 2025 · 8:30 AM UTC

Cuprina Holdings (Cayman) Limited Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

Read more

October 27, 2025 · 8:40 AM UTC

Cuprina Signs MOU with Singapore Biowaste Solutions to Integrate Medical Waste Management Technologies

Read more

October 6, 2025 · 8:30 AM UTC

Cuprina to Present Live, Answer Questions, at Skyline Signature Series™ on October 8th, 2025, at 11:00 AM ET

Read more